Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 12:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 976 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endothelial Clear all

Conditions: Dry Eye
Interventions: Miebo, Saline; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 12
States / cities: Glendale, California • Murrieta, California • Newport Beach, California + 9 more

Conditions: Myocardial Ischemia, Critical Illness, Endothelial Dysfunction
Interventions: Day Light, Placebo light, ICU Intense Light, ICU Placebo light; Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 90 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Fuchs' Endothelial Corneal Dystrophy
Interventions: Wearing of contact lens; Device
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Corneal Disease, Fuch's Dystrophy, Pseudophakic Corneal Edema
Interventions: corneas assigned by donor age group; Other
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 40 Years to 80 Years
Enrollment: 1,090 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2014
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Cardiovascular Disease
Interventions: Efavirenz, Rilpivirine; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Atherosclerosis
Interventions: Not listed
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Endothelial Dysfunction, Biochemical Markers
Interventions: Electronic Cigarette Aerosol; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 35 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Fuchs Endothelial Corneal Dystrophy, Corneal Endothelial Decompensation
Interventions: Descemet membrane endothelial keratoplasty; Procedure
Lead sponsor: Case Western Reserve University; Other
Eligibility: 30 Years to 93 Years
Enrollment: 570 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 14
States / cities: Atlanta, Georgia • Indianapolis, Indiana • Iowa City, Iowa + 10 more

Conditions: Coronary Artery Disease
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 21 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Endothelial Dysfunction, Metabolic Syndrome, Chronic Inflammation
Interventions: UCMSCs, BMMSCs, Placebo; Biological · Other
Lead sponsor: Joshua M Hare; Other
Eligibility: 21 Years to 95 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Wet Age-related Macular Degeneration
Interventions: Tarcocimab tedromer, Tabirafusp tedromer, Aflibercept; Drug
Lead sponsor: Kodiak Sciences Inc; Industry
Eligibility: 50 Years and older
Enrollment: 667 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 71
States / cities: Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 66 more

Conditions: Acute Lymphoblastic Leukemia
Interventions: Not listed
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 8 Years to 28 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Hypertension
Interventions: Chlorthalidone 12.5 mg, Hydrochlorothiazide 25 mg, Placebo; Drug
Lead sponsor: Creighton University; Other
Eligibility: 19 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Peripheral Arterial Disease
Interventions: Rivaroxaban 2.5 Mg Oral Tablet, Placebo, Aspirin 81Mg Ec Tab; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 40 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Obesity, Prehypertension, Hypertension
Interventions: Clonidine, Hydrochlorothiazide, Placebo; Drug
Lead sponsor: Gary L. Pierce; Other
Eligibility: 18 Years to 79 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Pre-hypertension, JNC 7 Stage I Hypertension
Interventions: Allopurinol, Placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 40 Years
Enrollment: 99 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Corneal Disease, Endothelial Corneal Dystrophy, Corneal Transplant Failure, Corneal Transplant Rejection
Interventions: Optical Coherence Tomography; Diagnostic Test
Lead sponsor: Nitin Vaswani; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hypertension
Interventions: Concord Grape Juice; Dietary Supplement
Lead sponsor: Boston University; Other
Eligibility: 21 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetic Retinopathy, Diabetic Macular Edema
Interventions: Prompt Sham, Prompt aflibercept, Deferred laser, Deferred aflibercept; Procedure · Drug
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 81
States / cities: Phoenix, Arizona • Tucson, Arizona • Huntington Beach, California + 68 more

Conditions: Obesity, Metabolic Syndrome, Hyperuricemia
Interventions: Rasburicase; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Sepsis, Severe Sepsis, Septic Shock
Interventions: Blood Collection and Assays; Diagnostic Test
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 910 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 7
States / cities: Birmingham, Alabama • Boston, Massachusetts • Manhasset, New York + 3 more

Conditions: Neovascular Age-Related Macular Degeneration
Interventions: Lucentis (Ranibizumab); Drug
Lead sponsor: University of Miami; Other
Eligibility: 50 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Cardiovascular Diseases
Interventions: Estradiol+MPA, Estradiol+Drospirenone; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 45 Years to 75 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Peripheral Vascular Disease, Lipid Disorder, Endothelial Dysfunction
Interventions: High Saturated Fat; Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 40 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Wauwatosa, Wisconsin

Search by objective public record fields.

A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.

Bright Light Exposure in Surgical Patients

Assessment of Corneal Endothelial Function Following Hypoxic Stress

Cornea Donor Study

Efavirenz Versus Rilpivirine on Vascular Function, Inflammation, and Oxidative Stress

Effects of PA-1 Transcriptional Regulation on Monocyte Function

Acute Effects of E-Cigarette Aerosol Inhalation

Effect of Donor Diabetes and Other Factors on Corneal Transplant Endothelial Cell Loss and Success at 5 Years

Biomarkers for Cardiovascular Disease

Infusion of Umbilical Cord Versus Bone Marrow Derived Mesenchymal Stem Cells to Evaluate Cytokine Suppression.

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK

Endothelial Function, Arterial Stiffness and Components

Chlorthalidone Compared to Hydrochlorothiazide on Endothelial Function

The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease

Vascular Dysfunction in Human Obesity Hypertension

Center of Research Translation (CORT) Project 2

Developing a Nationwide Registry to Track Longitudinal Clinical Outcomes of Corneal Surgery and Disease

Blood Pressure Lowering Effects of Grape Juice

Anti-VEGF Treatment for Prevention of PDR/DME

Effect of Reducing Uric Acid on Insulin Sensitivity and Oxidative Status

Endothelium in Severe Sepsis

Prospective OCT Study With Lucentis for Neovascular AMD (PrONTO Study)

Effect of Estradiol+Drospirenone Versus Estradiol+MPA on Endothelial Function

Effect of Plasma Ceramides on Peripheral Vascular Function